Evommune, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $187.3M
- Price
- $5.16
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.58%
- Volume
- 1.3M
About
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Quick stats
Shares outstanding36.3M
Computed float21.5M
Float / shares59.1%
Cash runway (months)21.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002044725
Websitehttps://www.evommune.com
AI Summary
AI-generated1/24
majorbullishclinical trial
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Evommune presented late-breaking Phase 2a proof-of-concept data for EVO301 in moderate-to-severe atopic dermatitis at the EADV 2026 Congress, meeting the primary endpoint with a 55% LS-mean EASI reduction at Week 12 versus 22% on placebo (p<0.01).
Responses deepened over time despite only two IV doses, with EASI-75 of 29% vs 9% placebo at Week 12 and a placebo-like safety profile including no conjunctivitis.
Biomarker data confirmed broad Th2, Th1, and Th17/22 pathway modulation, supporting IL-18 inhibition as a novel AD mechanism, with a subcutaneous Phase 2b dose-ranging trial planned for mid-2027.
Red flags
- Phase 2b start is not until mid-2027, implying extended cash burn ahead for a clinical-stage company
- Open-label-size trial (n=70) results may not replicate in larger Phase 2b